CALGB


Also found in: Acronyms.

CALGB

Cancer and Leukemia Group B. A national (US) clinical research group sponsored by the NCI, with its central office headquartered at the University of Chicago and its statistical centre located at Duke University.
References in periodicals archive ?
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase 3 trial (CALGB 9583).
Impact of Physical Activity on Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803.
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.
Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance).
The Breakthrough designation is primarily based upon the positive results from the Phase HI RATIFY (CALGB 10603) clinical trial.
Overall, 22% of the women were deemed by investigators to be eligible for no radiotherapy because they fit the criteria laid out in the CALGB (Cancer and Leukemia Group B) 9493 study: age 70 years or older, with T1N0, estrogen receptor-positive disease.
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.
(2006) (16) found in an analysis of the Intergroup CALGB study, that physically active patients with bowel cancer had 35% reduction in relapse rate in after chemotherapy.
Phase II trial of galiximab plus rituximab (CALGB trial) in untreated follicular lymphoma showed that the ORR was 72.1% including a 47.6% CR rate [100].
Socinski et al., "Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial," Journal of Clinical Oncology, vol.
More recently, the predictive power of hypertension was evaluated in a retrospective analysis of the phase III CALGB 90206 study, which demonstrated that patients on bevacizumab plus interferon who developed grade [greater than or equal to] 2 hypertension had significantly greater progression-free survival and overall survival times than patients who did not develop hypertension [23].